Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dna X (SONM) Revenue (2018 - 2025)

Dna X (SONM) has disclosed Revenue for 8 consecutive years, with $16.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue rose 7.94% year-over-year to $16.2 million, compared with a TTM value of $66.8 million through Sep 2025, up 17.66%, and an annual FY2024 reading of $58.3 million, down 37.74% over the prior year.
  • Revenue was $16.2 million for Q3 2025 at Dna X, up from $11.2 million in the prior quarter.
  • Across five years, Revenue topped out at $27.6 million in Q3 2023 and bottomed at $11.2 million in Q2 2025.
  • Average Revenue over 5 years is $17.3 million, with a median of $15.9 million recorded in 2021.
  • The sharpest move saw Revenue surged 124.47% in 2023, then plummeted 57.09% in 2024.
  • Year by year, Revenue stood at $15.9 million in 2021, then skyrocketed by 51.39% to $24.1 million in 2022, then tumbled by 44.32% to $13.4 million in 2023, then skyrocketed by 68.59% to $22.6 million in 2024, then fell by 28.39% to $16.2 million in 2025.
  • Business Quant data shows Revenue for SONM at $16.2 million in Q3 2025, $11.2 million in Q2 2025, and $16.7 million in Q1 2025.